Clinical Trial Search

Primary: Percentage of Participants With Treatment-emergent Adverse Events (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel…

Primary: Area Under the Concentration (AUC) Time Curve From Time Zero Extrapolated to Infinite Time (AUC [0-infinity]) of DTG — 90.9402 Hours*micrograms per milliliter

Primary: Percentage of Participants With Adverse Events (AEs) — 37.5; 37.5; 25.0; 50.0 Percentage of Participants

Primary: Number of Subjects With Adverse Events. — 12; 8; 0; 0 participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A — 1; 0; 2; 2 Participants

Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants

Primary: Part A: Number of Participants With Abemaciclib Dose Limiting Toxicities (DLTs) — 0; 1; 3 Participants

Primary: Maximum Tolerated Dose (MTD) of IMCgp100 Administered Weekly (Dose Escalation Part) — 600 ng/kg

Primary: PK Parameters for paclitaxel_AUC (0-52) — 3419; 3224 ng*hr/mL

Primary: Number of Participants Who Experienced Adverse Events Possibly Related to Study Intervention — 0; 6 Participants

Primary: Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve of Geometric Means of Serum Free Form of CS-7017 (R-150033) After Administration of CS-7017 and…

Primary: Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5…

Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) (Part 1) — 3; 4; 2; 0 Participants

Primary: Memory Testing — 1.20; .56; .82; 1.18 d' score

Primary: Number of Participants With All-causality and Treatment-related Treatment-emergent Adverse Events (TEAEs) — 17; 6; 8; 10 Participants